Single-Cell Multi-Omics Market Size, Share & Trends Analysis Report By Type (Single Cell Genomics, Single Cell Proteomics, Single Cell Transcriptomics, Single Cell Metabolomics), By Application (Oncology, Cell Biology, Neurology, Immunology, Others), By Technique (Single cell isolation and dispensing, Single cell analysis), By End User (Academic institutes, Contract research organizations, Pharmaceutical and biotech companies) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Market Overview

The global single-cell multi-omics market size was valued at USD 1.53 billion in 2021 and is predicted to reach USD 8.98 billion by 2030, increasing at a CAGR of 22.02% from 2022 to 2030.

Multiple types of molecules from a single cell are analysed using the single-cell multi-omics technique in order to gain greater biological knowledge than can be gained by investigating each molecular layer from separate cells. When compared with live cell fluorescence imaging, single-cell multi-omics is able to study the genome, epigenome and transcriptome, as well as the proteome and metabolome lines. There are several sorts of molecules in a single cell that can be measured using single-cell multi-omics. Allows data from many omics platforms to be combined. When it comes to disease processes, it is important to understand how each of these Omics layers interact. Genotypic and phenotypic single-cell sequencing is used to determine the mechanisms that govern illnesses and health.

Oncology, cell biology, neurology, stem cell, and immunology are just a few of the fields where single-cell multi-omics can be used. Single-cell omics is a powerful virology tool that should be used more frequently in the future for comprehending virus biology and virus-host cell interactions. Demand for single-cell technology solutions in clinical research in fields such as cancer, rare diseases, cell biology, and synthetic biology is fuelling the growth of this market. In order to better understand cell heterogeneity, tumour microenvironment, and antibody creation, single-cell technology is being developed. The global single-cell multi-omics market has grown because to a rise in oncology and uncommon illness cases.

Market Dynamics

Market drivers

Recent developments in technology employed act as a driver

The development of new single-cell technologies is making it easier to gain biological insights from individual cells. The technologies that deal with single cells may be roughly classified into two categories: those that allow for the separation of single cells and those that allow for the analysis of single cells. From the standpoint of cell separation, innovative techniques that can separate single living cells from a fluid sample, manipulate cells for image-based selection, utilize infrared laser capture, and those that can compartmentalize individual cells into picolitre drops are of significant interest. New single-cell platforms make separation and analysis easier. In some instances, both of the potential advancement of these technological innovations and their drawbacks are rapidly being developed, and they are proving to be of growing importance to researchers, especially in the field of global single cell multi-omics market.

Moreover, Technological breakthroughs, such as single-cell isolation and barcoding, allow DNA, mRNA, and protein profiles to be quantified at a single-cell resolution, driving market expansion. Significant expansion in the pharmaceutical business is favorably boosting market growth. Other factors, like the increased acceptance of personalized medicine for genetic disorders and improvements in healthcare infrastructure, are expected to boost market expansion.

Personalized medicine is becoming more popular as disposable money rises

The single-cell multi-omics sector is benefiting from rising disposable wealth in emerging economies and greater acceptance of personalized medicine for screening and detecting genetic abnormalities. Personalized medicine has the potential to simplify the genetic and molecular complications of diseases that have a high death rate and high health-care costs. This could provide important tools for prevention as well as suggestions about the disease's progression, and it could assist predict morbidity, fatality, and chronic illness indications far before in the disease's course.

New single-cell platforms make isolation and analysis easier, and in some cases, both the potential growth and barriers of these technology solutions are quickly becoming apparent, piquing researchers' curiosity, particularly in the field of single-cell genomics. The single-cell multi-omics market is expected to develop due to technological advancements in single-cell analysis products.

Market restraints

High costs associated with the analysis of single cells and the integration of data

It is anticipated that the high cost of analyzing single cells and the limited availability of massive online data storage and analysis platforms will act as barriers to the expansion of the single-cell multi-omics market. Additionally, there is a lack of qualified specialists, which is another factor that slows market expansion. It is anticipated that factors such as a deficiency in tools for computational analysis, restricted availability of massive online data storage and analysis platforms, and integration of data will all work to drag the market down.

Market opportunities

A rise in the amount of money invested in single-cell multi-omics research

It is anticipated that the expansion of single-cell multi-omics market participants into innovative research applications, including single-cell metabolomics, as well as increased collaborations and financing in the single-cell multi-omics research will give attractive growth prospects in the coming years. A variety of technological developments, including the development of single-cell separation and barcoding techniques that allow deoxyribonucleic acid (DNA), messenger ribonucleic acid (mRNA), and protein profiles to be evaluated at a single-cell resolution, will be providing a push to the market growth. This is expected to be one of the primary factors driving the growth of the market. As a direct result of this, the rapid expansion of the pharmaceutical business is having a constructive effect on the expansion of the market. It is projected that other factors, such as the growing use of customized medicine in the treatment of genetic disorders, together with the significant advancements towards the healthcare infrastructure, will open up new prospects in this market on a global scale. In addition, growing funding for research into single-cell multi-omics is predicted to generate profitable growth opportunities for players in the market.

Regional Analysis

The Global Single-Cell Multi-Omics Market is segmented by geography into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

North America is the dominating region among all others. The robust R&D infrastructure for biomedical researchers in North America, rising income levels, rapid implementation of modern techniques, enhanced single cell multi-omics analysis, and availability of major players across North America led to North America's dominance of the market in 2021. This resulted in North America accounting for almost half of the market.

During the time frame covered by this analysis, it is anticipated that North America will constitute a sizable portion of the single cell multi-omics market globally. It is anticipated that the market in the region will grow at a faster rate in the near future. This is primarily owing to the presence of advanced health care infrastructure, the rise in per capita income, the presence of state-of-the-art research labs and institutions, as well as continuous research tasks for the advent of new technologies in the region. During the period covered by the forecast, it is anticipated that Europe will come in second place behind North America.

The second greatest share is held by Europe, which is also predicted to see the highest CAGR over the course of the forecast period. In addition, it is anticipated that the single cell multi-omics markets in Germany and the United Kingdom will expand at a high compound annual growth rate (CAGR).

In Asia-Pacific, during the time covered by this research study, it is anticipated that the market for single-cell omics would develop at a significant compound annual growth rate (CAGR) as well. This is a result of an increasing trend toward preventative health care initiatives in the region.

Segmental Analysis

The Global Single-Cell Multi-Omics Market is divided into different segments according to the Type, Application, Technique, End-User and Geography.

By Type, Single Cell Genomics, Single Cell Proteomics, Single Cell Transcriptomics, and Single Cell Metabolomics are the four types of Single Cell Multi-Omics. The Single Cell Transcriptomics category is predicted to grow at a faster rate than the rest of the market. The term "transcriptome" refers to the collection of all transcription products in a cell under a certain physiological condition, including messenger RNA, ribosomal RNA, transport RNA, and non-coding RNA, whereas "mRNA" refers to all mRNAs.

By Application, the Single Cell Multi-Omics market is divided into four categories: oncology, cell biology, neurology, immunology, and others. During the projection period, oncology is expected to be the fastest-growing market. There are several distinct mutation sites or surface markers in the tumor environment, whether tumor cells or immune cells. The treatment plan's success is severely hampered by the body's extensive variety of cells, the timeliness of associated factor expression, and the dynamic process of change. As a result, the global Single Cell Multi-Omics Market has been propelled by oncology.

By Technique, the global single cell multi-omics market is divided into Single cell isolation & dispensing and Single cell analysis. Single-cell analysis accounted for the largest segment in 2021 and is anticipated to stay dominant during the forecast timeframe due to the fact that it is quick, effective, and delicate to maintain the native expression profiles benefit. In addition, it is expected to continue to be the technique with the highest market share.

By End-User, the global single cell multi-omics market is divided into Academic institutes, Contract research organizations and Pharmaceutical & biotech companies. The academic institutes segment of the market held the biggest market share in 2021 and is likely to be dominant during the forecast period, due to the spike in the number of research projects that are currently underway at academia and research laboratories.

By Geography, the Global Single Cell Multi-Omics Market is divided into the following regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa on the basis of Regional Analysis. Because of the robust research and development infrastructure for life science researches, the rapid adoption of advanced technologies, the improved single cell multi-omics analysis, and the presence of key players across North America, North America dominated the market in 2021 and accounted for nearly half of it.

Recent Developments

• May 2022 - The company Illumina, Inc., which is a global leader in DNA sequencing and array-based technologies, has announced that it has added a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSigh Oncology (TSO) Comprehensive (EU) test. This test is used to diagnose patients with cancer. This single test kit, which was just released, evaluates various tumour genes and biomarkers in order to identify the precise molecular profile of a patient's cancer.
• December 2021 - Qiagen partnered with Denovo Biopharma to provide a revolutionary biomarker solution in 2021. Through this partnership, the firms planned to create a blood-based companion diagnostic test to identify patients with Denovo Genomic Marker 1 likely to accept Denovo's investigational cancer medication DB102TM for treatment of diffuse large B-cell lymphoma, a common lymphoid malignancy.